Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) were granted approval by the U.S. Food and Drug Administration (FDA) for Basaglar (insulin glargine injection) 100 units/mL.
AstraZeneca has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort.
Eli Lilly and Company has elected Juan R. Luciano as a new member of its board, effective February 1, 2016.
Bristol-Myers Squibb has entered into a collaboration agreement with UCLA as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S.
Allergan has announced today that its first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D) – Viberzi – is now available by prescription in the U.S.
British drugmaker AstraZeneca Plc is in advanced talks to buy privately held cancer drug developer Acerta Pharma BV for more than $5 billion (£3.3 billion).
Johnson & Johnson Monday announced the formation of Verb Surgical Inc., an independent surgical solutions company, in collaboration with Verily Life Sciences…
Horizon Pharma plc has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.
Alvogen to market Natco’s generic Tamiflu capsules until 2017.
Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.